Your browser doesn't support javascript.
loading
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.
Liu, X; George, G C; Tsimberidou, A M; Naing, A; Wheler, J J; Kopetz, S; Fu, S; Piha-Paul, S A; Eng, C; Falchook, G S; Janku, F; Garrett, C; Karp, D; Kurzrock, R; Zinner, R; Raghav, K; Subbiah, V; Hess, K; Meric-Bernstam, F; Hong, D S; Overman, M J.
Afiliação
  • Liu X; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. xiaochunliu2013@gmail.com.
  • George GC; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. GGeorge2@mdanderson.org.
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. atsimber@mdanderson.org.
  • Naing A; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. anaing@mdanderson.org.
  • Wheler JJ; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. jjwheler@mdanderson.org.
  • Kopetz S; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit # 426, Houston, TX, 77030, USA. skopetz@mdanderson.org.
  • Fu S; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. siqingfu@mdanderson.org.
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. spihapau@mdanderson.org.
  • Eng C; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit # 426, Houston, TX, 77030, USA. ceng@mdanderson.org.
  • Falchook GS; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. Gerald.Falchook@scresearch.net.
  • Janku F; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. FJanku@mdanderson.org.
  • Garrett C; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit # 426, Houston, TX, 77030, USA. cgarrett@mdanderson.org.
  • Karp D; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. dkarp@mdanderson.org.
  • Kurzrock R; Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA, USA. rkurzrock@mail.ucsd.edu.
  • Zinner R; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. rzinner@mdanderson.org.
  • Raghav K; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit # 426, Houston, TX, 77030, USA. KPRaghav@mdanderson.org.
  • Subbiah V; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. VSubbiah@mdanderson.org.
  • Hess K; Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. khess@mdanderson.org.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. fmeric@mdanderson.org.
  • Hong DS; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Blvd, Houston, TX, 77030, USA. dshong@mdanderson.org.
  • Overman MJ; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit # 426, Houston, TX, 77030, USA. moverman@mdanderson.org.
BMC Cancer ; 15: 713, 2015 Oct 16.
Article em En | MEDLINE | ID: mdl-26474549
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Anticorpos Monoclonais Humanizados / Receptores ErbB / Anticorpos Monoclonais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Anticorpos Monoclonais Humanizados / Receptores ErbB / Anticorpos Monoclonais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos